Small study tests COVID pill levels in breast milk
NCT ID NCT05441215
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how much of the COVID-19 treatment nirmatrelvir/ritonavir (Paxlovid) gets into breast milk. Eight healthy breastfeeding women took the drug by mouth three times over two days. Researchers collected breast milk samples to measure drug levels, aiming to provide safety information for nursing mothers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirmatrelvir/ritonavir (Paxlovid)
What this could lead to
If successful, this study could help doctors understand whether nirmatrelvir/ritonavir is safe for breastfeeding women and their infants.
What could go wrong
This is a very small, early-phase study with only 8 participants. It measures drug levels in breast milk, not safety or effectiveness in treating illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium